RNA Stock Risk & Deep Value Analysis
RNA
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About RNA Stock
We analyzed RNA using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran RNA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is RNA Stock?
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Low
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for RNA?
- ⚠
Negative or mixed AOC 1001 Phase 3 data readout
- ⚠
Regulatory delays or outright rejection for AOC 1001
- ⚠
Increased competitive pressure from novel therapies
- ⚠
Significant capital raise leading to substantial dilution
Unlock RNA Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does RNA (RNA) Do?
Market Cap
$10.82B
Sector
Healthcare
Industry
Biotechnology
Employees
391
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in registrational clinical trials, such as Delpacibart etedesiran, which is in Phase 3 development stage for the treatment of people with myotonic dystrophy type 1; Delpacibart braxlosiran that is in Phase 1/2 development stage for treating facioscapulohumeral muscular dystrophy; and Delpacibart zotadirsen, which is in the Phase 2 EXPLORE44 open-label extension study for the treatment of Duchenne muscular dystrophy. The company is also developing precision cardiology candidates targeting rare genetic cardiomyopathies, including AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for protein kinase AMP-activated non-catalytic subunit gamma 2 syndrome. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Visit RNA WebsiteIs RNA Stock Undervalued?
Unlock the full AI analysis for RNA
Get the complete DVR score, risk analysis, and more
Does RNA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The AOC platform's unique ability to specifically deliver oligonucleotides to target tissues provides a distinct and durable competitive advantage, protected by strong intellectual property. Continued clinical success and expansion into new indications will further fortify this moat.
Moat Erosion Risks
- •Clinical trial failures that undermine platform validation
- •Emergence of superior or equally effective competing technologies
- •Patent challenges or eventual expiry
RNA Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive RNA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Estimated early May 2026)
- •Clinical trial updates for AOC 1025 and AOC 1044 at medical conferences
Medium-Term (6-18 months)
- •AOC 1001 Phase 3 MARINA-DM1 Topline Data Readout (Mid-Late 2026)
- •AOC 1001 Regulatory Filing (Late 2026 / Early 2027)
- •Initiation of new clinical trials for additional AOC candidates
Long-Term (18+ months)
- •AOC 1001 Commercial Launch (2027-2028, post-approval)
- •Expansion of AOC platform to new therapeutic areas
- •Establishment as a multi-product rare disease leader
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for RNA?
- ✓
Positive topline data from AOC 1001 MARINA-DM1 trial
- ✓
Successful regulatory filing and approval for AOC 1001
- ✓
Continued expansion and clinical progression of pipeline assets
- ✓
Cash burn rate relative to cash runway and potential financing needs
Bull Case Analysis
See what could go right with Premium
Compare RNA to Similar Stocks
See how RNA stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for RNA (RNA) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
